Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Samaraenergo reported for 6 months of 2023 by IFRS

9/6/23 SAGO

Alice" will speak in Kazakh by the end of the year

9/6/23 YNDX

KuibyshevAzot opened a new ammonium nitrate production facility

9/6/23 KAZT

Yandex Travel became the leader among aggregators for hotel search

9/6/23 YNDX

Aeroflot reissued 18 aircraft of Irish AerCap into Russian ownership

9/6/23 AFLT

Sual Partners filed a lawsuit against Rusal's Board of Directors

9/6/23 RUAL

Cosmos Hotel became the owner of the hotel construction project in Pskov

9/6/23 AFKS

OGK-2 plans additional issue of 48.28 bln shares

9/6/23 OGKB

UWC will conduct additional share issue to reduce debt

9/5/23 UWGN

Moscow Exchange is negotiating the issuance of an Islamic equivalent of bonds

9/5/23 MOEX